Table 2 The comparisons between before and after 6-week OXT treatment in all outcomes.

From: A clustering approach identifies an Autism Spectrum Disorder subtype more responsive to chronic oxytocin treatment

Subtype 1 (n = 15)

Subtype 2 (n = 26)

Variable

T test (pre vs. post)

P_FDR

Variable

T test (pre vs. post)

P_FDR

Measures of symptoms

     

ADOS-total

1.964

0.198

ADOS-total

5.293

0.009**

ADOS-CP

1.871

0.199

ADOS-CP

4.282

0.009**

ADOS-SA

2.162

0.163

ADOS-SA

3.207

0.017*

ADOS-RRB

−1.169

0.371

ADOS-RRB

3.202

0.017*

ABAS-GAC

−2.23

0.261

ABAS-GAC

−2.974

0.020*

SCQ

−0.124

0.390

SCQ

1.497

0.185

CSQ

1.215

0.698

CSQ

1.858

0.116

RBS

1.416

0.698

RBS

2.396

0.049*

Eye-tracking

     

Social

−0.923

0.452

Social

−2.459

0.049*

Angry eyes

−3.089

0.094

Angry eyes

−2.361

0.049*

Angry nose

1.514

0.262

Angry nose

−1.469

0.185

Fear eyes

2.474

0.115

Fear eyes

2.038

0.088

Fear nose

0.092

0.928

Fear nose

−1.110

0.295

Happy eyes

−2.633

0.115

Happy eyes

−1.748

0.132

Happy nose

1.543

0.262

Happy nose

−1.437

0.185

Neutral eyes

−2.927

0.094

Neutral eyes

−0.470

0.642

Neutral nose

1.332

0.315

Neutral nose

−2.468

0.049*

Endocrine

     

Saliva OXT

  

Saliva OXT

  
  1. ADOS-total Autism Diagnostic Observation Schedule-2-total score, CP comparison score, SA social affect, RRB restrictive and repetitive behavior, ABAS-GAC adaptive behavior assessment system-II, global adaptive composite, SCQ social communication quotient, CSQ caregiver strain questionnaire, RBS repetitive behavior scale—revised, OXT oxytocin.
  2. *p < 0.5; **p < 0.01; FDR-corrected.
Back to article page